Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to -$18.9 million.

  • Vanda Pharmaceuticals' Net Income towards Common Stockholders fell 324.23% to -$22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.2 million, marking a year-over-year decrease of 413.85%. This contributed to the annual value of -$18.9 million for FY2024, which is 853.29% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Net Income towards Common Stockholders of -$18.9 million as of FY2024, which was down 853.29% from $2.5 million recorded in FY2023.
  • In the past 5 years, Vanda Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $33.2 million in FY2021 and a low of -$18.9 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$3.4 million, with a median of $2.5 million in 2023.
  • In the last 5 years, Vanda Pharmaceuticals' Net Income towards Common Stockholders surged by 42.06% in 2021 and then slumped by 853.29% in 2024.
  • Vanda Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at $23.3 million in 2020, then soared by 42.06% to $33.2 million in 2021, then plummeted by 81.07% to $6.3 million in 2022, then plummeted by 60.02% to $2.5 million in 2023, then slumped by 853.29% to -$18.9 million in 2024.